MedTrace Logo

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

NCT02592356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2024-03-05

No results posted yet for this study

Summary

The goal of this clinical research study is to learn about possible weight, muscle, and/or fat loss in patients receiving cabozantinib or lenvatinib.

Conditions

  • Differentiated Thyroid Gland Carcinoma
  • Malignant Adrenal Gland Pheochromocytoma
  • Malignant Paraganglioma
  • Thyroid Gland Medullary Carcinoma

Interventions

PROCEDURE

Computed Tomography

Correlative studies

PROCEDURE

Dual X-ray Absorptiometry

Correlative studies

PROCEDURE

Physical Examination

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Cabozantinib

DRUG

Lenvatinib

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Naifa L Busaidy · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-16
Primary Completion
2024-03-01
Completion
2024-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02592356 on ClinicalTrials.gov